Establishment Labs/$ESTA
1D1W1MYTD1Y5YMAX
Capital at risk
About Establishment Labs
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
- Ticker
- $ESTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,004
- Headquarters
- Austin, United States
- Website
- www.establishmentlabs.com
ESTA Metrics
BasicAdvanced
$2.1B
-
-$1.29
1.09
-
Price and volume
Market cap
$2.1B
Beta
1.09
52-week high
$97.59
52-week low
$36.61
Average daily volume
457K
Financial strength
Current ratio
3.837
Quick ratio
2.274
Long term debt to equity
12.203
Total debt to equity
12.203
Interest coverage (TTM)
-0.68%
Profitability
EBITDA (TTM)
-8.984
Gross margin (TTM)
70.49%
Net profit margin (TTM)
-15.82%
Operating margin (TTM)
-7.63%
Effective tax rate (TTM)
18.08%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-3.44%
Return on equity (TTM)
-175.30%
Valuation
Price to revenue (TTM)
8.781
Price to book
99.65
Price to tangible book (TTM)
196.31
Price to free cash flow (TTM)
-51.946
Free cash flow yield (TTM)
-1.93%
Free cash flow per share (TTM)
-1.376
Growth
Revenue change (TTM)
38.55%
Earnings per share change (TTM)
-58.15%
3-year revenue growth (CAGR)
11.54%
3-year earnings per share growth (CAGR)
-19.28%
What the Analysts think about ESTA
Analyst ratings (Buy, Hold, Sell) for Establishment Labs stock.
Analyst projections of the future price of Establishment Labs stock.
Bulls say / Bears say
Accelerating adoption of its minimally invasive platform contributed significantly to Q2 revenue growth and margin improvement, highlighting strong product differentiation (Reuters)
Continued growth of the higher-margin U.S. business drove gross margin expansion to 70.6% in Q2 2026, underscoring successful U.S. market penetration (Reuters)
The company raised full-year 2026 revenue guidance to $269 million–$271 million, signaling management’s confidence in sustained growth and market share gains (Reuters)
Net loss in Q2 2026 was $11.75 million, missing analyst expectations and underscoring persistent bottom-line pressure (Stockopedia)
Earnings per share of $0.39 in Q2 2026 missed consensus of $0.34, reflecting ongoing challenges in achieving profitability (Stockopedia)
Wall Street’s median 12-month price target of $98.00 implies only about 7.4% upside from recent levels, suggesting limited investor upside potential (Stockopedia)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
ESTA Financial Performance
Revenues and expenses
ESTA Earnings Performance
Company profitability
Upcoming events
No upcoming events
ESTA News
AllArticlesVideos
Funds containing ESTA
AllEURGBPUSD
Fund name | Fund size | $ESTA weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.15% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.07% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.